Rapid responses are electronic comments to the editor. They enable our users
to debate issues raised in articles published on bmj.com. A rapid response
is first posted online. If you need the URL (web address) of an individual
response, simply click on the response headline and copy the URL from the
browser window. A proportion of responses will, after editing, be published
online and in the print journal as letters, which are indexed in PubMed.
Rapid responses are not indexed in PubMed and they are not journal articles.
The BMJ reserves the right to remove responses which are being
wilfully misrepresented as published articles or when it is brought to our
attention that a response spreads misinformation.
From March 2022, the word limit for rapid responses will be 600 words not
including references and author details. We will no longer post responses
that exceed this limit.
The word limit for letters selected from posted responses remains 300 words.
aspirin resistance has been recognised in several conditions
particularly diabetes and hyperlipidaemias. thus usual dose of aspirin may
be insufficient. being itself a weak antiplatelet agent, higher doses are
tempting but associated with side effects both local possibly at site of
retinopathy and systemic. what may be more logical is a combination of low
dose aspirin with clopidogrel a Gp 11b/111a antiplatelet agent.current
literature already moots use of aspirin in every diabetic for protection
against atherosclerosis.
aspirin+clopidogrel in diabetic retinopathy
aspirin resistance has been recognised in several conditions
particularly diabetes and hyperlipidaemias. thus usual dose of aspirin may
be insufficient. being itself a weak antiplatelet agent, higher doses are
tempting but associated with side effects both local possibly at site of
retinopathy and systemic. what may be more logical is a combination of low
dose aspirin with clopidogrel a Gp 11b/111a antiplatelet agent.current
literature already moots use of aspirin in every diabetic for protection
against atherosclerosis.
Competing interests:
None declared
Competing interests: No competing interests